French biotech CellProthera welcomes three exceptional talents to its executive management team
17.11.2021 18:43:00 EET | Business Wire | Press release
CellProthera SAS, a clinical stage biotechnology company developing a novel cell therapy for the regeneration of damaged heart tissue and other impaired organs, has strengthened its executive management team to foster the development of its main clinical program and extend it to new therapeutic indications.
Ibon Garitaonandia is appointed Chief Scientific Officer (CSO). His extensive experience in drug discovery and in the development of novel stem cell products will accelerate the translation of CellProthera’s cell therapy platform into new treatments for regenerative medicine. He has 15 years’ experience in stem cell research and regenerative medicine, and has worked at the Richmond Research Institute in London, Histocell in Spain and International StemCell Corporation in California, the first company to receive global regulatory approval to conduct a human pluripotent stem cell-based clinical trial for Parkinson’s disease.
Henk Streefkerk, MD PhD, takes the role of Chief Medical Officer (CMO). He brings decades of leadership in clinical research to boost the strategic development of the company and advance its pipeline of novel therapeutic solutions. After graduating from the University Medical Center Utrecht, Henk worked as Clinical Pharmacologist for Organon/Schering-Plough in the Netherlands. He then joined Actelion in Switzerland before taking the positions of Translational Medicine Expert and later Senior Brand Safety Leader with Novartis in Basel. After Novartis, he worked as Medical Director and Chief Medical Officer of a biotech specialized in oncology in Basel.
Olivier Friedrich is appointed Chief Financial Officer (CFO). His solid history of helping companies and start-ups to scale up in their development journey is key for CellProthera as it enters its next stage of development. A lecturer at EM Strasbourg in Finance and Regulation, Olivier brings 15 years of experience in corporate finance, internal control, accounting and tax matters. He held leadership positions with Ernst & Young for more than 10 years, leading financial audits and due diligence transactions for a wide spectrum of industrial firms and as CFO, supporting the cash and financing management of listed companies in the energy and car industry.
“The arrival of these three talents - all experts in their field - in the executive management team is a great boost to our ambitious, multi-indications development program and position us ideally to accelerate our pathway to market.", stated Matthieu de Kalbermatten, Chairman of CellProthera. “The wealth of their international experience will be useful to shape and steer the company effectively during the next clinical and regulatory stages.”
CellProthera develops a medical innovation that enables a heart damaged by a heart attack to regenerate by injecting stem cells originated from the patient's own blood.
As such, each patient becomes his own source of medicine!
The stem cell product ProtheraCytes® is obtained from a proprietary technology developed by CellProthera. It is injected into the heart tissue to be regenerated. In a few months, the heart muscle will regain its functionality, thus avoiding future treatments that are often severe, and in some cases, the need for a heart transplant.
Contact us! www.cellprothera.com/fr/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211117006054/en/
Contact information
Press contact: Mediatiser – Antoine Monnier / amonnier@mediatiser.tv
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fastly Joins DIMPACT to Collaborate on Digital Sustainability8.7.2026 15:00:00 EEST | Press release
Fastly, Inc. (NASDAQ: FSLY), a leading global edge cloud platform, today announced it has become a participant of DIMPACT, the coalition of leading organizations working to align industry changemakers and policymakers around meaningful, science-based solutions that reduce the environmental impacts of serving digital media products. As the first edge cloud platform provider to join the coalition, Fastly brings critical, real-world edge network data and infrastructure expertise and a transparent approach to emissions calculation and reporting to help major media, streaming, and publishing companies understand and optimize their digital carbon footprints. “We’re thrilled to welcome Fastly to the DIMPACT initiative. Their participation strengthens DIMPACT's ability to advance a more accurate, data-driven approach to measuring and reducing digital emissions,” said Jason Bell, Director at SLR Consulting and Executive Sponsor of DIMPACT. “Accurately calculating digital emissions requires a de
PubNub Introduces Blocks.ai: The Control Plane and Network Layer For AI Agents8.7.2026 15:00:00 EEST | Press release
PubNub introduces Blocks.ai today, a global network to connect and control agents across all agent frameworks, providers, and APIs. Blocks.ai lets developers reach their existing AI agents regardless of where they are hosted. Blocks Network supports all AI agent use cases without opening inbound ports, setting up tunnels, changing DNS, or modifying firewall rules. For more than a decade, PubNub has been the infrastructure and platform for real-time connectivity supporting billions of devices, now, PubNub delivers Blocks Network connecting the Internet of Agents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708521206/en/ AI agents have become increasingly critical to businesses who want control over their models, code, and data. But once those agents are running locally or behind a firewall, making them reachable from custom frontends can require brittle infrastructure work. This is a key reason why McKinsey estimates th
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development8.7.2026 15:00:00 EEST | Press release
STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's Good Manufacturing Practices (GMP) iPSC lines, and will offer the matched GMP lines to developers worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708212795/en/ Partnership pairs GMP-manufactured iPSC lines with matched RUO equivalents, giving developers well-characterized, donor-eligible starting materials from early research through clinical development. Supporting comparability data for the RUO and GMP lines to be presented at the 2026 ISSCR Annual Meeting in Montréal, Canada
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 15:00:00 EEST | Press release
The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer of its kind, combining quantum error correction with NISQ qubits. The system will be delivered in 2027, followed by a series of upgrades delivered in multiple phases with an increasing number of logical qubits. The IQM Halocene H4 and the upgraded systems will enable LUMI consortium users, for the first time, to develop and implement Quantum Error Correction (QEC) concepts on a world-leadi
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manifestations, often associated with substantial physical and psychosocial burden, the lack of targeted treatment makes the disease hard to control,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “This Breakthrough Therapy designation demonstrates that enpatoran has the potential to redefine how we approach lupus, by addressing the visible burden of rash, while potentially driving benefit beyond the skin. We look forward to working with the FDA to potentially bring this much-needed option to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom